Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 23 tags : Positive save search
Global Next Generation Public and Personal Safety Applications and Services Market Report 2022-2027: Public Safety LTE and Upcoming 5G Network will Make Positive impacts on Public Safety Systems
Published: 2022-05-23 (Crawled : 19:00) - prnewswire.com
NOKBF | News | $3.75 210K
|
Electronic Technology
|
| O: -0.73%
H: 1.47%
C: 0.8%
SAPGF | News | $176.433 1.9K
|
Technology Services
|
| O: 0.28%
H: 0.59%
C: -0.73%
SAP | News | $187.0 4.95% 590K
|
Technology Services
|
| O: -0.18%
H: 0.0%
C: 0.0%
NOC | $474.4 0.73% 380K
|
Electronic Technology
|
| O: -0.26%
H: 3.7%
C: 3.41%
NOK | News | $3.65 -1.08% 9.3M
|
Electronic Technology
|
| O: -0.61%
H: 0.61%
C: 0.0%
GD | $293.75 0.84% 200K
|
Electronic Technology
|
| O: -0.24%
H: 2.22%
C: 1.68%
ERIC | News | $5.305 0.86% 8M
|
Electronic Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
CMTL | $1.625 -7.67% 330K
|
Electronic Technology
|
| O: -0.65%
H: 3.13%
C: 2.8%
services report positive market 5g
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | News | $169.965 1.24% 890K
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
ASND | $146.045 2.78% 61K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial china positive results phase 3
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
Published: 2022-05-23 (Crawled : 14:20) - globenewswire.com
WINT | $5.51 1.1% 49K
|
Health Technology
|
| O: 3.51%
H: 10.36%
C: -14.26%
heart cardiology positive
Kyndryl Positioned as a Leader in 2022 Gartner® Magic Quadrant™ for Managed Mobility Services, Global
Published: 2022-05-23 (Crawled : 13:20) - prnewswire.com
KD | $20.43 2.25% 200K
|
Information
|
| O: -2.19%
H: 0.43%
C: -4.78%
IT | $449.94 1.55% 39K
|
Commercial Services
|
| O: 0.41%
H: 0.0%
C: 0.0%
gartner positive
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
tukysa topline trial positive results cancer her2- phase 2 her2
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 6.07%
H: 8.26%
C: -13.24%
ctp-543 topline trial positive phase 3
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.575 0.31% 2.5M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Gainers vs Losers
| 88% | 12% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.75 79.52% 1.5M
|
CZOO | $8.77 75.75% 11M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.14 39.56% 7.6M
|
Finance
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
CMAX | $4.12 28.35% 65K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.